{
    "xml": "<topic id=\"PHP1576\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/alteplase\" basename=\"alteplase\" title=\"ALTEPLASE\">\n<title>ALTEPLASE</title>\n<body>\n<data name=\"vtmid\">27638005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_431464079\" title=\"Tissue plasminogen activators\">Tissue plasminogen activators</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" title=\"FIBRINOLYTICS\" namespace=\"/drug-classes/fibrinolytics\">FIBRINOLYTICS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\n<p outputclass=\"synonyms\">rt-PA; Tissue-type plasminogen activator</p>\n</body>\n<topic id=\"PHP60254\" outputclass=\"indicationsAndDose\" rev=\"1.40\" parent=\"/drugs/alteplase\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute myocardial infarction, accelerated regimen</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 65 kg)</p>\n<p>Initially 15&#8239;mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 0.75&#8239;mg/kg, to be given over 30 minutes, then (by intravenous infusion) 0.5&#8239;mg/kg, to be given over 60 minutes, maximum total dose of 100&#8239;mg administered over 90 minutes.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 65 kg and above)</p>\n<p>Initially 15&#8239;mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 50&#8239;mg, to be given over 30 minutes, then (by intravenous infusion) 35&#8239;mg, to be given over 60 minutes, maximum total dose of 100&#8239;mg administered over 90 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute myocardial infarction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 10&#8239;mg, to be initiated within 6&#8211;12 hours of symptom onset, followed by (by intravenous infusion) 50&#8239;mg, to be given over 60 minutes, then (by intravenous infusion) 10&#8239;mg for 4 infusions, each 10&#8239;mg infusion dose to be given over 30 minutes, total dose of 100&#8239;mg over 3 hours; maximum 1.5&#8239;mg/kg in patients less than 65&#8239;kg.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 10&#8239;mg, to be given over 1&#8211;2 minutes, followed by (by intravenous infusion) 90&#8239;mg, to be given over 2 hours, maximum 1.5&#8239;mg/kg in patients less than 65&#8239;kg.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute stroke (under specialist neurology physician only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;79 years</p>\n<p>Initially 900&#8239;micrograms/kg (max. per dose 90&#8239;mg), treatment <b>must</b> begin within 4.5 hours of symptom onset, to be given over 60 minutes, the initial 10% of dose is to be administered by intravenous injection and the remainder by intravenous infusion.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60305\" outputclass=\"contraindications\" rev=\"1.20\" parent=\"/drugs/alteplase\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<sectiondiv outputclass=\"additionalContraindications\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithIndications\">\n<p outputclass=\"title\">When used for acute ischaemic stroke</p>\n<p>\n<ph outputclass=\"contraindication\">convulsion accompanying stroke</ph>; <ph outputclass=\"contraindication\">history of stroke in patients with diabetes</ph>; <ph outputclass=\"contraindication\">hyperglycaemia</ph>; <ph outputclass=\"contraindication\">hypoglycaemia</ph>; <ph outputclass=\"contraindication\">severe stroke</ph>; <ph outputclass=\"contraindication\">stroke in last 3 months</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60240\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/alteplase\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Contra-indicated if concomitant treatment with oral anticoagulants.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60191\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/alteplase\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Risk of cerebral bleeding increased in acute stroke</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60329\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.21\" parent=\"/drugs/alteplase\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityContraindications\">\n<sectiondiv>\n<p>Contraindicated if history of hypersensitivity to gentamicin (residue from manufacturing process).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60137\" outputclass=\"monitoringRequirements\" parent=\"/drugs/alteplase\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">acute ischaemic stroke</ph>\n</p>\n<p>Monitor for intracranial haemorrhage, and monitor blood pressure (antihypertensive recommended if systolic above 180&#8239;mmHg or diastolic above 105&#8239;mmHg).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60336\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/alteplase\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Actilyse</i>\n<tm tmtype=\"reg\"/>), give intermittently or continuously in Sodium chloride 0.9%; dissolve in water for injections to a concentration of 1&#8239;mg/mL or 2&#8239;mg/mL and infuse intravenously; alternatively dilute the solution further in the infusion fluid to a concentration of not less than 200&#8239;micrograms/mL; not to be infused in glucose solution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60107\" outputclass=\"nationalFunding\" rev=\"1.19\" parent=\"/drugs/alteplase\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA264</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Alteplase for the treatment of acute ischaemic stroke (September 2012)</p>\r\n<p> Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if: </p>\r\n<ul>\r\n<li>treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, <i>and</i>\r\n</li>\r\n<li>intracranial haemorrhage has been excluded by appropriate imaging techniques.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA264\">www.nice.org.uk/TA264</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1576-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/alteplase\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77050\" title=\"Powder and solvent for solution for injection\" namespace=\"/drugs/alteplase/powder-and-solvent-for-solution-for-injection\">Powder and solvent for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77042\" title=\"Powder and solvent for solution for infusion\" namespace=\"/drugs/alteplase/powder-and-solvent-for-solution-for-infusion\">Powder and solvent for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78101\" namespace=\"/treatment-summaries/fibrinolytic-drugs\" title=\"Fibrinolytic drugs\" count=\"4\" rel=\"backlink\">Fibrinolytic drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78168\" namespace=\"/treatment-summaries/management-of-stroke\" title=\"Management of stroke\" count=\"1\" rel=\"backlink\">Management of stroke</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" namespace=\"/drug-classes/fibrinolytics\" title=\"FIBRINOLYTICS\" count=\"1\" rel=\"link\">FIBRINOLYTICS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77050\" namespace=\"/drugs/alteplase/powder-and-solvent-for-solution-for-injection\" title=\"Powder and solvent for solution for injection\" count=\"1\" rel=\"link\">Powder and solvent for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77042\" namespace=\"/drugs/alteplase/powder-and-solvent-for-solution-for-infusion\" title=\"Powder and solvent for solution for infusion\" count=\"1\" rel=\"link\">Powder and solvent for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP1576",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/alteplase",
    "basename": "alteplase",
    "title": "ALTEPLASE",
    "vtmid": "27638005",
    "drugClassification": [
        "Tissue plasminogen activators"
    ],
    "inheritsFromClass": [
        "FIBRINOLYTICS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "rt-PA",
        "Tissue-type plasminogen activator"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Acute myocardial infarction, accelerated regimen",
                        "html": "Acute myocardial infarction, accelerated regimen"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 15 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 0.75 mg/kg, to be given over 30 minutes, then (by intravenous infusion) 0.5 mg/kg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes.",
                        "html": "<p>Initially 15&#8239;mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 0.75&#8239;mg/kg, to be given over 30 minutes, then (by intravenous infusion) 0.5&#8239;mg/kg, to be given over 60 minutes, maximum total dose of 100&#8239;mg administered over 90 minutes.</p>",
                        "ageGroup": "(body-weight up to 65 kg)"
                    },
                    {
                        "textContent": "Initially 15 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 30 minutes, then (by intravenous infusion) 35 mg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes.",
                        "html": "<p>Initially 15&#8239;mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 50&#8239;mg, to be given over 30 minutes, then (by intravenous infusion) 35&#8239;mg, to be given over 60 minutes, maximum total dose of 100&#8239;mg administered over 90 minutes.</p>",
                        "ageGroup": "(body-weight 65 kg and above)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acute myocardial infarction",
                        "html": "Acute myocardial infarction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 10 mg, to be initiated within 6&#8211;12 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 60 minutes, then (by intravenous infusion) 10 mg for 4 infusions, each 10 mg infusion dose to be given over 30 minutes, total dose of 100 mg over 3 hours; maximum 1.5 mg/kg in patients less than 65 kg.",
                        "html": "<p>Initially 10&#8239;mg, to be initiated within 6&#8211;12 hours of symptom onset, followed by (by intravenous infusion) 50&#8239;mg, to be given over 60 minutes, then (by intravenous infusion) 10&#8239;mg for 4 infusions, each 10&#8239;mg infusion dose to be given over 30 minutes, total dose of 100&#8239;mg over 3 hours; maximum 1.5&#8239;mg/kg in patients less than 65&#8239;kg.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Pulmonary embolism",
                        "html": "Pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 10 mg, to be given over 1&#8211;2 minutes, followed by (by intravenous infusion) 90 mg, to be given over 2 hours, maximum 1.5 mg/kg in patients less than 65 kg.",
                        "html": "<p>Initially 10&#8239;mg, to be given over 1&#8211;2 minutes, followed by (by intravenous infusion) 90&#8239;mg, to be given over 2 hours, maximum 1.5&#8239;mg/kg in patients less than 65&#8239;kg.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acute stroke (under specialist neurology physician only)",
                        "html": "Acute stroke (under specialist neurology physician only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 900 micrograms/kg (max. per dose 90 mg), treatment must begin within 4.5 hours of symptom onset, to be given over 60 minutes, the initial 10% of dose is to be administered by intravenous injection and the remainder by intravenous infusion.",
                        "html": "<p>Initially 900&#8239;micrograms/kg (max. per dose 90&#8239;mg), treatment <b>must</b> begin within 4.5 hours of symptom onset, to be given over 60 minutes, the initial 10% of dose is to be administered by intravenous injection and the remainder by intravenous infusion.</p>",
                        "ageGroup": "18&#8211;79 years"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "cautionsOrContraindicationsWithIndications": [
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "convulsion accompanying stroke",
                "html": "convulsion accompanying stroke",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "history of stroke in patients with diabetes",
                "html": "history of stroke in patients with diabetes",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "hyperglycaemia",
                "html": "hyperglycaemia",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "hypoglycaemia",
                "html": "hypoglycaemia",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "severe stroke",
                "html": "severe stroke",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "stroke in last 3 months",
                "html": "stroke in last 3 months",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for acute ischaemic stroke",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                }
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Contra-indicated if concomitant treatment with oral anticoagulants.",
                "html": "<p>Contra-indicated if concomitant treatment with oral anticoagulants.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Risk of cerebral bleeding increased in acute stroke",
                        "html": "Risk of cerebral bleeding increased in acute stroke",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "allergyAndCrossSensitivity": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Contraindicated if history of hypersensitivity to gentamicin (residue from manufacturing process).",
                "html": "<p>Contraindicated if history of hypersensitivity to gentamicin (residue from manufacturing process).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "When used for acute ischaemic stroke",
                    "html": "When used for <ph outputclass=\"indication\">acute ischaemic stroke</ph>",
                    "indications": [
                        "acute ischaemic stroke"
                    ]
                },
                "textContent": "Monitor for intracranial haemorrhage, and monitor blood pressure (antihypertensive recommended if systolic above 180 mmHg or diastolic above 105 mmHg).",
                "html": "<p>Monitor for intracranial haemorrhage, and monitor blood pressure (antihypertensive recommended if systolic above 180&#8239;mmHg or diastolic above 105&#8239;mmHg).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Actilyse ), give intermittently or continuously in Sodium chloride 0.9%; dissolve in water for injections to a concentration of 1 mg/mL or 2 mg/mL and infuse intravenously; alternatively dilute the solution further in the infusion fluid to a concentration of not less than 200 micrograms/mL; not to be infused in glucose solution.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Actilyse</i>\n<tm tmtype=\"reg\"/>), give intermittently or continuously in Sodium chloride 0.9%; dissolve in water for injections to a concentration of 1&#8239;mg/mL or 2&#8239;mg/mL and infuse intravenously; alternatively dilute the solution further in the infusion fluid to a concentration of not less than 200&#8239;micrograms/mL; not to be infused in glucose solution.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA264",
                        "label": "www.nice.org.uk/TA264"
                    }
                ],
                "fundingIdentifier": "NICE TA264",
                "textContent": "Alteplase for the treatment of acute ischaemic stroke (September 2012) Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if: treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and intracranial haemorrhage has been excluded by appropriate imaging techniques.\n\nwww.nice.org.uk/TA264",
                "html": "<p outputclass=\"title\">Alteplase for the treatment of acute ischaemic stroke (September 2012)</p> <p> Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if: </p> <ul> <li>treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, <i>and</i> </li> <li>intracranial haemorrhage has been excluded by appropriate imaging techniques.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA264\">www.nice.org.uk/TA264</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77050",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77042",
                "label": "Powder and solvent for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78101",
                "label": "Fibrinolytic drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78168",
                "label": "Management of stroke",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34567",
                "label": "FIBRINOLYTICS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77050",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77042",
                "label": "Powder and solvent for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}